Loading…
Radiopharm Theranostics Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in RADX.
▼ -63.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $5.22 | $4.49 | |
| P/S | — | 3397.6x | 6907.9x |
| P/B | — | 275.6x | 73.5x |
| EPS | -$5.28 | -$37.23 | |
| Profit margin | — | -1055.27% | -16024.28% |
| ROE | — | -85.60% | -170.50% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATYRaTYR PHARMA INC | $0.36 | — | 0.7x | — | -98.68% | $34.96M |
| CNTXContext Therapeutics Inc. | $0.38 | — | 0.9x | — | -76.14% | $35.25M |
| QNCXQuince Therapeutics, Inc. | $33.75 | — | — | — | -153.84% | $34.33M |
| BDMDBaird Medical Investment Holdings Ltd | $1.12 |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Company description provided by Yahoo Finance.
| — |
| 0.7x |
| — |
| -77.60% |
| $35.82M |
| NSYSNortech Systems Inc | $11.84 | 33.8x | 1.0x | — | 3.00% | $33.79M |
| HBIOHarvard Bioscience Inc | $7.92 | — | 4.9x | — | -89.95% | $36.05M |